The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: What's in it for African and Middle Eastern rheumatologists

Clinical Rheumatology

Volumn 31, Issue 9, 2012, Pages 1281-1287

  Alawadhi, Adel ^a   Alawneh, Khaldoon ^b   Alzahrani, Zeyad Ahmed ^c  

^a KUWAIT UNIVERSITY   (Kuwait)

^b JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^c KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Africa; Ankylosing spondylitis; Antitumor necrosis factor; Immunogenicity; Middle East; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; NEUTRALIZING ANTIBODY; RITUXIMAB; TOCILIZUMAB;

ADAPTIVE IMMUNITY; AFRICA; ANKYLOSING SPONDYLITIS; BIOLOGICAL THERAPY; CROSS REACTION; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; MIDDLE EAST; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS;

AFRICA; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; BIOLOGICAL THERAPY; EPITOPES; HUMANS; IMMUNE SYSTEM; MIDDLE EAST; RHEUMATOLOGY; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867850258     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2040-2     Document Type: Review

References (39)

1. Wolbink GJ, Aarden LA, Dijkmans BA (2009) Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 21:211-215
2. EU summary of product characteristics: Remicade (2012) Centocor BV, Leiden
3. EU summary of product characteristics: Humira (2012) Abbott Biotechnology Deutschland GmBH, Wiesbaden
4. Prescribing information: Rituximab (2012). Biogen Idec Inc and Genentech, South San Francisco
5. EU summary of product characteristics: Enbrel (2012) Pfizer, Hampshire
6. EU summary of product characteristics: Cimzia (2011) UCB Pharma, Bruselles
7. EU summary of product characteristics: MabThera (2012) Roche Pharma AG, Grenzach-Wyhlen
8. EU summary of prescribing characteristics: Simponi (2012) Centocor BV, Leiden
9. EU summary of product characteristics: RoActemra (2011) Roche Registration, Welwyn Garden City
10. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916 (Pubitemid 32224400)
11. Kvien TK (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(2 Suppl 1):1-12 (Pubitemid 38269929)
12. Badsha H, Kong KO, Tak PP (2008) Rheumatoid arthritis in the United Arab Emirates. Clin Rheumatol 27:739-742
13. Mody GM, Cardiel MH (2008) Challenges in management of rheumatoid arthritis in developing countries. Best Pract Res Clin Rheumatol 22:621-641
14. Schellekens H (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720-1740 (Pubitemid 35440946)
15. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E (2010) Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 38:82-89
16. Hwang WY, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36:3-10 (Pubitemid 40558811)
17. Jahn EM, Schneider CK (2009) How to systematically evaluate immunogenicity of therapeutic protiens-regulatory considerations. N Biotechnol 25:280-286
18. Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34(5 Suppl 1):19-22
19. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68:1739-1745
20. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L,Wolbink GJ (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305:1460-1468
21. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfá E (2010) Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 38:82-89
22. Fleischmann R, Shealy D (2003) Developing a new generation of TNF alpha antagonists for the treatment of rheumatoid arthritis. Mol Interv 6:310-318
23. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54:711-715
24. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921-926 (Pubitemid 46999794)
25. de Vries MK, Wolbink GJ, Stapel SQ, de Vrieze H, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66:1252-1254 (Pubitemid 47309746)
26. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66:921-926 (Pubitemid 46999794)
27. Arends S, Lebbink HR, Spoorenberg et al (2010) The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28:661-668
28. Maini RN, Breedveld RC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563 (Pubitemid 28459913)
29. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ (2004) Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 50:353-363 (Pubitemid 38198818)
30. de VriesMK, van der Horst-Bruinsma IE et al (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68:531-535
31. Rubbert-Roth A, Finckh A (2009) Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 11(Supp 11): S1
32. Gomez-Reino JJ, Carmona L, BIOBADASER Group (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29
33. Hyrich KL, Lunt M,Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13-20 (Pubitemid 46106174)
34. Iannone F, Trotta F, Montecucco C et al (2007) Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 66:249-252 (Pubitemid 46226063)
35. Jamnitski A, Bartelds GM, Nurmohamed MT et al (2011) The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 70:284-288
36. Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A (2009) Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68:1856-1862
37. Marchesoni A, Zaccara E, Goria R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann NY Acad Sci 1173:837-846
38. Hetland ML, Christensen IJ, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22-32
39. Moots RJ, Haraoui B, Matacci-Cerinic M et al (2011) Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 29:26-34